HIGH-DOSE DONOR BONE MARROW INFUSIONS TO ENHANCE ALLOGRAFT SURVIVAL

Abstract

The results suggest that dose and timing of DBMC infusions may be important variables affecting allograft survival. A randomized prospective trial is now in progress to compare group 3 DBMC infusion protocol with controls receiving OLTX alone.